The Effect of Early Repeat Atrial Fibrillation (AF) Ablation on AF Recurrence
Launched by LIVERPOOL HEART AND CHEST HOSPITAL NHS FOUNDATION TRUST · Sep 13, 2013
Trial Information
Current as of June 03, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged over 18 years
- • Current pattern of paroxysmal AF (defined as electrocardiogram (ECG)-proven episodes of AF which are self-limiting and last less than 7 days on each occasion, or which were cardioverted electrically or pharmacologically less than 48 hours from onset)
- • Due to undergo pulmonary vein isolation by radiofrequency (RF) ablation
- Exclusion Criteria:
- • Inability or unwillingness to receive oral anticoagulation with warfarin or alternative anticoagulant drug
- • Previous ablation procedure for AF
- • Unwillingness or inability to complete the required follow-up arrangements
- • Current pattern of persistent (episodes of AF which last longer than 7 days or which last longer than 48 hours but require electrical or pharmacological cardioversion) or permanent AF
- • Prior prosthetic mitral valve replacement or severe structural cardiac abnormality
- • Reversible cause for AF
- • Known infiltrative cardiomyopathy
- • Known severe left ventricular systolic function (ejection fraction \<35%)
- • Pregnancy
About Liverpool Heart And Chest Hospital Nhs Foundation Trust
Liverpool Heart and Chest Hospital NHS Foundation Trust is a leading healthcare institution in the UK, specializing in cardiothoracic care and research. Renowned for its commitment to clinical excellence and innovative practices, the Trust plays a pivotal role in advancing medical knowledge through rigorous clinical trials. With a multidisciplinary team of experts, it focuses on developing and evaluating new treatments and interventions for heart and lung conditions, ensuring high standards of patient safety and care. The Trust's dedication to enhancing patient outcomes and contributing to the field of cardiology and thoracic medicine positions it as a key player in the NHS's research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Liverpool, Merseyside, United Kingdom
Patients applied
Trial Officials
Dhiraj Gupta, DM, MD, FRCP
Principal Investigator
Liverpool Heart and Chest Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials